Search results for "Platelet"

showing 10 items of 786 documents

Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group stu…

2005

Complete remission (CR) in patients with acute myeloid leukaemia (AML) is the primary endpoint for the evaluation of induction treatment and treatment strategies. However, the choice and application of the criteria for a haematological CR can often become a subject of debate because of regeneration more than 5% blasts may be present at the time of response evaluation; platelet and neutrophil recovery may be incomplete and marrow cellularity can vary. This study examined the individual parameters for CR in 1250 adult patients with de novo AML treated according to three successive study protocols. Patients with < or =5% blasts showed the best overall survival (OS) and the lowest relapse risk …

AdultMaleRiskmedicine.medical_specialtyPathologyAdolescentcomplete remissionMINIMAL RESIDUAL DISEASEDIAGNOSISGastroenterologyTHERAPYDisease-Free SurvivalAMLRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPlateletacute myeloid leukaemiaLymphocyte CountProportional Hazards ModelsrevisedHematologycriteriaProportional hazards modelbusiness.industryINDUCTIONRemission InductionCancerHematologyMiddle AgedCOLONY-STIMULATING FACTORmedicine.diseaseMinimal residual diseaseCANCERHIGH-DOSE CYTARABINELeukemiamedicine.anatomical_structureLeukemia MyeloidAcute DiseaseFemaleBone marrowbusinessBritish Journal of Haematology
researchProduct

Methodological considerations to determine the effect of exercise on brain-derived neurotrophic factor levels.

2015

Objectives: Physical exercise up-regulates brain-derived neurotrophic factor (BDNF) in the brain and blood. However, there is yet no consensus about the adequate blood processing conditions to standardize its assessment. We aimed to find a reliable blood sample processing method to determine changes in BDNF due to exercise. Design and methods: Twelve healthy university students performed an incremental cycling test to exhaustion. At baseline, immediately after exercise, and 30 and 60 min of recovery, venous blood was drawn and processed under different conditions, i.e. whole blood, serum coagulated for 10 min and 24 h, total plasma, and platelet-free plasma. BDNF concentration was measured …

AdultMaleSerummedicine.medical_specialtyHemoconcentrationClinical BiochemistryPhysical exerciseHemoconcentraciónPlasmaEnzyme-linked immunosorbent assayNeurotrophic factorsInternal medicinePlasma sanguineoSurveys and QuestionnairesMedicineHumansPlateletEducación físicaExerciseWhole bloodBrain-derived neurotrophic factorBlood Specimen Collectionbusiness.industryBrain-Derived Neurotrophic FactorGeneral MedicineVenous bloodHemoconcentrationWhole bloodEndocrinologyHomogeneousbusinessEnergy MetabolismClinical biochemistry
researchProduct

Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura.

2003

Abstract Thrombotic thrombocytopenic purpura (TTP) is an uncommon hematologic thrombotic disorder characterized by fever, hemorrhagic and neurologic signs. The advent of plasma exchange has dramatically improved the prognosis of this disease, which was once inevitably fatal. However, mortality rates remain significant. Antiplatelet drugs have been widely used in combination with plasma exchange. In this pilot study we investigated the effects of an adjunctive therapy consisting of the continuous, intravenous infusion of dipyridamole, a modality of administration that has not been previously tested in this setting. Sixteen untreated TTP patients, diagnosed consecutively at our clinic, receiv…

AdultMaleTime FactorsCombination therapyThrombotic thrombocytopenic purpuraPilot ProjectsMethylprednisolonelaw.inventionRandomized controlled trialRefractorylawRecurrencemedicineHumansPlateletIn patientProspective StudiesInfusions IntravenousPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryPlatelet CountMortality rateRemission InductionHematologyDipyridamoleMiddle Agedmedicine.diseaseCombined Modality TherapyDipyridamoleTreatment OutcomeAnesthesiaFemalebusinessPlatelet Aggregation Inhibitorsmedicine.drugTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct

Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease

1986

The dose-dependent inhibition of platelet aggregation by the chemically stable, prostacyclin-mimetic, iloprost, was studied in patients suffering from stage II-III peripheral arterial obliterative disease (PAOD). The study was designed as a randomized placebo-controlled cross-over trial. Iloprost was administered i.v. to six patients at doses of 0.5, 1.0, 2.0 or 3.0 ng/kg X min for 4 h, with an interval of 2-3 days between the infusions. During iloprost infusion, systolic and diastolic arterial blood pressure, heart rate and blood flow in the affected limb remained unchanged. In contrast, there was a considerable, dose-dependent inhibition of ADP- and thrombin-induced platelet aggregation a…

AdultMaleTime FactorsPlatelet AggregationDiastoleHemodynamicsArterial Occlusive DiseasesPlaceboRandom AllocationDrug DiscoveryHeart ratemedicineHumansPlateletIloprostGenetics (clinical)AgedDose-Response Relationship Drugbusiness.industryHemodynamicsCardiovascular AgentsGeneral MedicineMiddle AgedEpoprostenolBlood pressureAnesthesiaCardiovascular agentDrug EvaluationMolecular MedicineFemalelipids (amino acids peptides and proteins)businesscirculatory and respiratory physiologyIloprostmedicine.drugKlinische Wochenschrift
researchProduct

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

2007

This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country.24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored.Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsTime FactorsAdolescentBone diseasemedicine.medical_treatmentDiseaseWeight GainSeverity of Illness IndexHemoglobinsGeneticsmedicineHumansIn patientChildGenetics (clinical)ChemotherapyGaucher DiseasePlatelet CountRomaniabusiness.industryLiver DiseasesRomaniannutritional and metabolic diseasesAnemiaEnzyme replacement therapyMiddle Agedmedicine.diseaseCombined Modality TherapyThrombocytopeniaRecombinant Proteinslanguage.human_languageSurgeryHexosaminidasesTreatment OutcomeSplenomegalyQuality of LifeSplenectomylanguageGlucosylceramidaseFemaleBone DiseasesbusinessFollow-Up StudiesJournal of Inherited Metabolic Disease
researchProduct

A Cytologic Assay for Diagnosis of Food Hypersensitivity in Patients With Irritable Bowel Syndrome

2010

BACKGROUND &amp; AIMS: A percentage of patients with symptoms of irritable bowel syndrome (IBS) suffer from food hypersensitivity (FH) and improve on a food-elimination diet. No assays have satisfactory levels of sensitivity for identifying patients with FH. We evaluated the efficacy of an in vitro basophil activation assay in the diagnosis of FH in IBS-like patients. METHODS: Blood samples were collected from 120 consecutive patients diagnosed with IBS according to Rome II criteria. We analyzed in vitro activation of basophils by food allergens (based on levels of CD63 expression), as well as total and food-specific immunoglobulin (Ig)E levels in serum. Effects of elimination diets and dou…

AdultMalefood hypersensitivitySettore MED/09 - Medicina InternaAdolescentCytologic assay; food hypersensitivity; irritable bowel diseaseCytological Techniquesirritable bowel diseasePlatelet Membrane GlycoproteinsImmunoglobulin ESensitivity and SpecificityIrritable Bowel SyndromeYoung AdultAntigenAntigens CDElimination dietmedicineAnimalsHumansYoung adultCells CulturedIrritable bowel syndromeCytologic assayHepatologybiologyCD63Tetraspanin 30business.industryGastroenterologyAllergensImmunoglobulin EMiddle Agedmedicine.diseaseBasophilsBasophil activationImmunologybiology.proteinFemaleAntibodybusinessClinical Gastroenterology and Hepatology
researchProduct

Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives

2000

Previous evidence has demonstrated a relationship between growth factors and cardiovascular diseases. This study was aimed at evaluating levels of some endothelium-derived growth factors, and their relationship with microalbuminuria (MAU), in essential hypertension. Ninety-nine mild-moderate essential hypertensives (EH) and 25 healthy controls were studied. All patients underwent 24-h blood pressure monitoring, serum endothelin-1 (ET-1), basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF), and 24-h MAU assays. Later, EH were divided into two subsets consisting of microalbuminurics (MAU >11 microg/min) and nonmicroalbuminurics (MAU <11 microg/min). In microalbumin…

AdultMalemedicine.hormonemedicine.medical_specialtyPlatelet-derived growth factorBasic fibroblast growth factorBlood PressureEnzyme-Linked Immunosorbent AssayEssential hypertensionEndothelinschemistry.chemical_compoundInternal medicineInternal MedicinemedicineAlbuminuriaHumansPlatelet-Derived Growth FactorCreatinineProteinuriaEndothelin-1business.industryBlood Pressure Monitoring Ambulatorymedicine.diseaseEndocrinologyBlood pressurechemistrySpectrophotometryCreatinineHypertensionFemaleFibroblast Growth Factor 2MicroalbuminuriaEndothelium Vascularmedicine.symptombusinessBiomarkersAmerican Journal of Hypertension
researchProduct

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.

2018

Background Autoimmune thrombotic thrombocytopenic purpura (iTTP) is caused by autoantibody-mediated severe a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) deficiency leading to micro-angiopathic haemolytic anaemia (MAHA) and thrombocytopenia with organ damage. Patients survive with plasma exchange (PEX), fresh frozen plasma replacement and corticosteroid treatment. Anti-CD20 monoclonal antibody rituximab is increasingly used in patients resistant to conventional PEX or relapsing after an acute bout. Objective This retrospective observational study focused on the relapse rate and possible influencing factors including treatment with rituximab first…

AdultMalemedicine.medical_specialtyAdolescentautoantibodiesThrombotic thrombocytopenic purpuraADAMTS13 ProteinRelapse rate030204 cardiovascular system & hematologyGastroenterologyAutoimmune Diseases03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsRecurrenceInternal medicinehemic and lymphatic diseasesCellular Haemostasis and PlateletsMedicineHumansImmunologic Factorsclinical studiesYoung adultChildADAMS/ADAMTS13Retrospective StudiesPurpura Thrombotic Thrombocytopenicbusiness.industryRetrospective cohort studyHematologythrombotic thrombocytopenic purpura (TTP/HUS)Middle Agedmedicine.diseaseAntigens CD20ADAMTS13PurpuraTreatment Outcome030220 oncology & carcinogenesisRituximabFemaleFresh frozen plasmamedicine.symptombusinessRituximabmedicine.drugFollow-Up StudiesThrombosis and haemostasis
researchProduct

The Neutrophil-to-Lymphocyte ratio as a marker of recovery status in patients with severe dental infection.

2017

Background The aim of the study was to assess the value of pretreatment neutrophil/lymphocyte (N/L) ratio and mean platelet volume (MPV) and the correlation between these markers with progression in patients with severe odontogenic infection. Material and Methods A cohort of 100 patients with severe odontogenic infection were divided into 2 groups according to their length of hospital stay. The N/L ratio and MPV was measured in all patients. The correlation in all patients between preoperative fever, preoperative antibiotic doses, postoperative antibiotic doses, total antibiotic doses and hospital stay with N/L ratio and MPV were analyzed. The Youden index was used to identify the optimal c…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classNeutrophilsLymphocyteAntibioticsInfectionsGastroenterologySeverity of Illness Index03 medical and health sciencesLeukocyte CountYoung Adult0302 clinical medicineInternal medicineSeverity of illnessmedicineHumansLymphocytesNeutrophil to lymphocyte ratioMean platelet volumeChildGeneral DentistryRetrospective StudiesOdontogenic infectionOral Medicine and Pathologybusiness.industryResearchRemission InductionRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryAnti-Bacterial Agentsmedicine.anatomical_structureOtorhinolaryngologyTooth Diseases030220 oncology & carcinogenesisCohortUNESCO::CIENCIAS MÉDICASDisease ProgressionSurgeryFemalebusinessMean Platelet VolumeBiomarkersMedicina oral, patologia oral y cirugia bucal
researchProduct

Effect of interleukin-3 pretreatment on granulocyte/macrophage colony-stimulating factor induced mobilization of circulating haemopoietic progenitor …

1995

Recombinant human colony stimulating factors (CSFs) as single agents are increasingly used for mobilizing peripheral blood progenitor cells (PBPCs) for stem cell transplantation. We have shown in rhesus monkeys that interleukin-3 (IL-3) pretreatment markedly potentiated the increase in PBPC numbers of subsequent administration of granulocyte/macrophage-CSF (GM-CSF). Here we studied the effect of IL-3 pretreatment on GM-CSF-induced mobilization of PB progenitors in patients who were potential candidates for autologous stem cell transplantation (n = 16). Patients were treated with GM-CSF at a dose of 5 micrograms/kg/d for 5 d and after a treatment free interval received another cycle of GM-CS…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentGranulocyteLeukocyte CountInternal medicinemedicineHumansProgenitor cellInterleukin 3business.industryPlatelet CountGranulocyte-Macrophage Colony-Stimulating FactorHematologyColony-stimulating factorHematopoietic Stem CellsTransplantationCytokineEndocrinologymedicine.anatomical_structureGranulocyte macrophage colony-stimulating factorImmunologyErythrocyte CountFemaleInterleukin-3Stem cellbusinessmedicine.drugBritish journal of haematology
researchProduct